Cargando…

Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting

BACKGROUND: We model the epidemiological impact of providing isoniazid preventive therapy (IPT) to South African adolescents, among whom HIV prevalence is low, latent tuberculosis (TB) prevalence is high, and school-based programs may enable population-level coverage. METHODS: We simulate a dynamic...

Descripción completa

Detalles Bibliográficos
Autores principales: Rhines, Allison S., Feldman, Marcus W., Bendavid, Eran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150186/
https://www.ncbi.nlm.nih.gov/pubmed/30096067
http://dx.doi.org/10.1097/QAD.0000000000001959
_version_ 1783356938684203008
author Rhines, Allison S.
Feldman, Marcus W.
Bendavid, Eran
author_facet Rhines, Allison S.
Feldman, Marcus W.
Bendavid, Eran
author_sort Rhines, Allison S.
collection PubMed
description BACKGROUND: We model the epidemiological impact of providing isoniazid preventive therapy (IPT) to South African adolescents, among whom HIV prevalence is low, latent tuberculosis (TB) prevalence is high, and school-based programs may enable population-level coverage. METHODS: We simulate a dynamic compartmental model of age-structured HIV and TB coepidemics in South Africa. HIV dynamics are modeled by infection status, CD4(+) cell count, and antiretroviral therapy; TB dynamics are modeled by disease stage, diagnosis, treatment, and IPT status. We analyze the effects of continuous IPT coverage among adolescents from 5 (baseline) to 90%. RESULTS: Our model is calibrated to WHO and the Joint United Nations Programme on HIV/AIDS epidemiological estimates. In simulations, increasing IPT coverage to 50% among adolescents reduced active TB incidence by 5–34%. Increasing coverage to 90% led to a 9–40% reduction in active TB incidence. Expanded IPT access causes TB incidence to decline in the general population of HIV-positive individuals, as well as in adult HIV-positive individuals. CONCLUSION: Targeting IPT to a secondary school population with high latent TB prevalence and low-HIV prevalence, in which risk of false-negative diagnosis of active TB is low and IPT benefits are more established, could have substantial benefits to adolescents and spillover benefits to the adult population.
format Online
Article
Text
id pubmed-6150186
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-61501862018-10-12 Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting Rhines, Allison S. Feldman, Marcus W. Bendavid, Eran AIDS Basic Science BACKGROUND: We model the epidemiological impact of providing isoniazid preventive therapy (IPT) to South African adolescents, among whom HIV prevalence is low, latent tuberculosis (TB) prevalence is high, and school-based programs may enable population-level coverage. METHODS: We simulate a dynamic compartmental model of age-structured HIV and TB coepidemics in South Africa. HIV dynamics are modeled by infection status, CD4(+) cell count, and antiretroviral therapy; TB dynamics are modeled by disease stage, diagnosis, treatment, and IPT status. We analyze the effects of continuous IPT coverage among adolescents from 5 (baseline) to 90%. RESULTS: Our model is calibrated to WHO and the Joint United Nations Programme on HIV/AIDS epidemiological estimates. In simulations, increasing IPT coverage to 50% among adolescents reduced active TB incidence by 5–34%. Increasing coverage to 90% led to a 9–40% reduction in active TB incidence. Expanded IPT access causes TB incidence to decline in the general population of HIV-positive individuals, as well as in adult HIV-positive individuals. CONCLUSION: Targeting IPT to a secondary school population with high latent TB prevalence and low-HIV prevalence, in which risk of false-negative diagnosis of active TB is low and IPT benefits are more established, could have substantial benefits to adolescents and spillover benefits to the adult population. Lippincott Williams & Wilkins 2018-09-24 2018-09-19 /pmc/articles/PMC6150186/ /pubmed/30096067 http://dx.doi.org/10.1097/QAD.0000000000001959 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Basic Science
Rhines, Allison S.
Feldman, Marcus W.
Bendavid, Eran
Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting
title Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting
title_full Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting
title_fullStr Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting
title_full_unstemmed Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting
title_short Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting
title_sort modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high hiv-prevalence setting
topic Basic Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150186/
https://www.ncbi.nlm.nih.gov/pubmed/30096067
http://dx.doi.org/10.1097/QAD.0000000000001959
work_keys_str_mv AT rhinesallisons modelingtheimplementationofpopulationlevelisoniazidpreventivetherapyfortuberculosiscontrolinahighhivprevalencesetting
AT feldmanmarcusw modelingtheimplementationofpopulationlevelisoniazidpreventivetherapyfortuberculosiscontrolinahighhivprevalencesetting
AT bendavideran modelingtheimplementationofpopulationlevelisoniazidpreventivetherapyfortuberculosiscontrolinahighhivprevalencesetting